Teva Pharmaceutical Industries Ltd Prices €1.5B and $3.2B Senior Notes

What Happened Teva Pharmaceutical Industries Ltd announced on Sept. 10, 2026 (press release) and filed an 8‑K that underwriting agreements were entered into (dated Sept. 9, 2026) to sell five series of senior notes. The issuers (Teva Finance II, III and IV) and Teva as guarantor agreed to offer euro and U.S. dollar‑denominated notes totaling €1.5 billion and $3.2 billion in principal. The sales are expected to close on Sept. 16, 2026 and were made under the company’s Form S‑3ASR registration (File No. 333-284770) and a prospectus supplement filed Sept. 8, 2026.

Key Details

• 2033 Euro Notes: €1,000,000,000 principal, 4.250% coupon, priced at 98.756% of par.
• 2036 Euro Notes: €500,000,000 principal, 4.625% coupon, priced at 98.327% of par.
• 2034 USD Notes: $1,000,000,000 principal, 5.500% coupon, priced at 98.659% of par.
• 2037 USD Notes: $1,000,000,000 principal, 5.750% coupon, priced at 98.520% of par.
• 2032 USD Notes: $1,200,000,000 principal, 5.250% coupon, priced at 98.993% of par.
• Underwriters include BNP Paribas, Citigroup, Goldman Sachs and J.P. Morgan (as lead representatives). Offering registered under the Securities Act via the company’s existing S‑3 shelf.

Why It Matters This filing means Teva is raising substantial long‑term debt across multiple maturities and currencies. When the deals close, Teva’s consolidated debt will increase by the principal amounts shown and the company will incur fixed coupon interest obligations at the stated rates. For investors, important takeaways are the added long‑term funding, the interest rates (which affect future interest expense), the staggered maturities (2032–2037) and the company’s continued access to capital markets.